(VIANEWS) – The Market ended the session with GENEURO (GNRO.PA) rising 15.55% to €1.10 on Monday, after four consecutive sessions in a row of losses. CAC 40 jumped 0.18% to €7,246.93, following the last session’s upward trend on what was a somewhat positive trend exchanging session today.
GENEURO’s last close was €0.95, 72.64% below its 52-week high of €3.48.
About GENEURO
GeNeuro SA, a clinical-stage biopharmaceutical company, develops drugs for the treatment of neurodegenerative and autoimmune diseases. The company's lead therapeutic candidate is temelimab, a monoclonal antibody that neutralizes a pathogenic protein of the HERV-W family; treats type 1 diabetes; and treats chronic inflammatory demyelinating polyneuropathy. It also developing GNK301. In addition, It has cooperative research and development agreements with The National Institute of Neurological Disorders and Stroke to develop novel therapeutic antibodies for the treatment of amyotrophic lateral sclerosis; and Academic centers to develop inflammatory psychosis, as well as a research collaboration agreement with International Center for Infectiology Research; and with Northwestern University for human endogenous retrovirus W envelope protein (HERV-W ENV) in long-haul COVID patients. The company was incorporated in 2006 and is headquartered in Plan-les-Ouates, Switzerland.
Earnings Per Share
As for profitability, GENEURO has a trailing twelve months EPS of €-0.54.
Yearly Top and Bottom Value
GENEURO’s stock is valued at €1.10 at 21:31 EST, under its 52-week low of €1.13.
Volatility
GENEURO’s last week, last month’s, and last quarter’s current intraday variation average was a negative 5.03%, a negative 2.68%, and a positive 3.59%.
GENEURO’s highest amplitude of average volatility was 5.03% (last week), 4.00% (last month), and 3.59% (last quarter).
Volume
Today’s last reported volume for GENEURO is 5858 which is 40.74% below its average volume of 9886.
More news about GENEURO (GNRO.PA).
